Exelixis PT receives Investment Bank Analyst Rating Update
Exelixis (NASDAQ:EXEL) reported Q2 EPS of $0.28, $0.09 better than the analyst estimate of $0.19. Revenue for the quarter came in at $419.4 million versus the consensus estimate of...
Exelixis (NASDAQ:EXEL) reported Q1 EPS of $0.26, $0.13 better than the analyst estimate of $0.13. Revenue for the quarter came in at $356 million versus the consensus estimate of...
Biotechnology stocks represent companies that research, develop or market healthcare-related therapies or products. They typically use living organisms, biological systems, or...
Exelixis (NASDAQ:EXEL), Inc. EXEL recently announced its preliminary results for the fourth quarter and full-year 2021 and provided financial guidance for full-year 2022.In 2021,...
Exelixis (NASDAQ:EXEL), Inc. EXEL reported earnings of 9 cents per share in the fourth quarter of 2020, beating the Zacks Consensus Estimate of 3 cents. The bottom-line figure...
Exelixis, Inc. is an oncology focused biotechnology company. The Company is engaged in the discovery, development, and commercialization of medicines to treat cancers. Its cabozantinib molecule, is an inhibitor of multiple tyrosine kinases including MET, AXL, VEGF receptors and RET. Cabozantinib is approved as CABOMETYX tablets used for advanced renal cell carcinoma (RCC), both alone and in combination with Bristol-Myers Squibb Company's (BMS) OPDIVO (nivolumab), for hepatocellular carcinoma (HCC) and for radioactive iodine (RAI)-refractory differentiated thyroid cancer (DTC). Cabozantinib is also approved as COMETRIQ capsules for metastatic medullary thyroid cancer (MTC). Its other two products are COTELLIC, an inhibitor of MEK approved as part of multiple combination regimens to treat specific forms of advanced melanoma and MINNEBRO an oral, non-steroidal, selective blocker of the mineralocorticoid receptor (MR) approved the treatment of hypertension.
|Average||27.15 (+73.17% Upside)|
|No. of Analysts||13|